Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
CC transcript
AVADEL PHARMACEUTICALS PLC (AVDL) Create: Alert

All | News | Filings
Date FiledTypeDescription
11/05/2018 8-K Investor presentation, Quarterly results
Docs: "AVADEL PHARMACEUTICALS PLC UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Revenues:",
"Presentation materials dated November 5, 2018, issued by Avadel Pharmaceuticals plc"
08/07/2018 8-K Investor presentation, Quarterly results
Docs: "AVADEL PHARMACEUTICALS PLC UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Revenues:",
"Presentation materials dated August 7, 2018, issued by Avadel Pharmaceuticals plc"
05/02/2018 8-K Investor presentation, Quarterly results
Docs: "Avadel Pharmaceuticals Reports First Quarter 2018 Results NOCTIVA™ launch underway across the U.S. FT 218 granted Orphan Drug Designation Generated revenue of $33.3 million",
"Presentation materials dated May 2, 2018, issued by Avadel Pharmaceuticals plc",
"Avadel Launches NOCTIVA™, the First and Only FDA-Approved Treatment for Nocturia Due to Nocturnal Polyuria Innovative product now available in the United States for condition that interrupts sleep for over 40 million Americans"
03/08/2018 8-K Investor presentation, Quarterly results
Docs: "Avadel Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Results",
"Presentation materials"
11/08/2017 8-K Investor presentation, Quarterly results
Docs: "Avadel Pharmaceuticals Reports Third Quarter 2017 Results Total Revenues for the Third Quarter Were $39.7 million Full Year Revenue Guidance of $165-$175 million Unchanged Acquired License for Noctiva&#8482",
"Presentation materials"
09/05/2017 8-K Quarterly results
05/11/2017 8-K Form 8-K - Current report
03/07/2017 8-K Form 8-K - Current report
11/07/2016 8-K Investor presentation, Quarterly results
Docs: "Flamel Technologies Reports Third Quarter 2016 Results Total Revenues Were $32.1 Million 2016 Revenue Guidance Increased to $133 to $143 Million REST-ON Phase III Trial of Micropump Sodium Oxybate Initiated",
"Presentation materials"
08/08/2016 8-K Investor presentation, Quarterly results
Docs: "Flamel Technologies Reports Second Quarter 2016 Results",
"Presentation materials"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy